# An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc

Source: https://onco.cc/trials/nct06991556/  
OnCo record `nct06991556` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abiraterone acetate, Enzalutamide in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) is a phase 2 interventional study registered as NCT06991556 by Novartis Pharmaceuticals, with 168 participants enrolled, started 2025-07-07 and due to reach its primary completion in 2032-02-13. Interventions recorded: JSB462, Abiraterone, Enzalutamide. Conditions listed: Metastatic Hormone-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06991556
- Phase: 2
- Setting: A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 168

## Sources

- ClinicalTrials.gov NCT06991556: https://clinicaltrials.gov/study/NCT06991556

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct06991556.json